IBRX News & Events

ImmunityBio announced completion of enrollment in its Phase 2 clinical trial evaluating Anktiva plus Bacillus Calmette-Guerin versus BCG alone in patients with BCG-naive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors.

ImmunityBio is up 14.7%, or $1.28 to $9.98.

ImmunityBio is up 25.2%, or $2.19 to $10.89.